LINC02162: A Long Intergenic Non-Protein Coding RNA (G105374624)

Target Name: LINC02162

NCBI ID: G105374624

LINC02162

Other Name(s): long intergenic non-protein coding RNA 2162 | Long intergenic non-protein coding RNA 2162

LINC02162: A Long Intergenic Non-Protein Coding RNA

Non-Protein Coding RNAs (NP-C RNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These RNAs are not directly encoded by protein-coding genes, but instead are generated by the process of RNA splicing, which allows the cell to generate a diverse set of RNA molecules.NP-C RNAs have been identified in a wide range of organisms, including humans, and have been shown to play important roles in various cellular processes, including gene regulation, DNA replication, and metabolism. In this article, we will focus on LINC02162, a long intergenic non-protein-coding RNA (lncRNA), and its potential as a drug target or biomarker.

LINC02162 is a transcribed RNA molecule that contains 2162 exons and is located between the exons of the non-coding RNA (ncRNA) gene HASN. HASN is a tumor suppressor gene that has been implicated in the development and progression of various diseases, including cancer. LINC02162 has been shown to play a role in the regulation of gene expression in cancer cells.

To better understand the function of LINC02162, researchers have used a variety of techniques to study its properties. One approach has been to use RNA sequencing (RNA-seq) to determine the expression levels of LINC02162 in different cell types and to identify its binding partners .RNA-seq is a powerful tool for analyzing the expression of RNA molecules in a wide range of organisms, including cancer cells. By analyzing the expression levels of LINC02162 in different cell types, researchers have been able to identify its potential targets and to gain insights into its functions.

Another approach that has been used to study LINC02162 is to use small RNA sequencing (siRNA-seq).siRNA-seq is a technique that allows researchers to identify and quantify specific RNA molecules in a sample. By using siRNA-seq to study the expression of LINC02162, researchers have been able to determine the levels of this RNA molecule in different cell types and to identify its binding partners.

In addition to these techniques, researchers have also used high-throughput mass spectrometry (HGST) to identify the RNA molecule's function. HGST is a technique that allows researchers to identify and quantify specific RNA molecules based on their mass-to-charge ratio. By using HGST to study the function of LINC02162, researchers have been able to determine that this RNA molecule plays a role in cell signaling.

The potential drug targets for LINC02162 are vast and varied. LINC02162 has been shown to play a role in the regulation of cell proliferation, which is a critical step in the development of cancer. In addition, LINC02162 has also been shown to play a role in the regulation of cell apoptosis, which is a natural process that helps cells to remove damaged or unnecessary proteins.

LINC02162 has also been shown to play a role in the regulation of cell migration. During the development of cancer, cells often migrate away from the site of origin in order to establish new tumors. LINC02162 has also been shown to play a role in the regulation of cell migration. cell migration by controlling the movement of specific proteins to the front of the cell.

In addition to its potential as a drug target or biomarker, LINC02162 also has potential as a research tool for studying the functions of other genes. By using techniques such as RNA-seq, siRNA-seq, and HGST, researchers have been able to study the properties of LINC02162 and to understand its functions in different cellular

Protein Name: Long Intergenic Non-protein Coding RNA 2162

The "LINC02162 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02162 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets